Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection.

Marianne MartinelloChloe OrkinGraham CookeSanjay BhaganiEdward GaneRanjababu KulasegaramDavid ShawElise TuKathy PetoumenosPhilippa MarksJason GrebelyGregory J DoreMark NelsonGail V Matthews

Published in: Hepatology (Baltimore, Md.) (2020)

Glecaprevir/pibrentasvir for 6 weeks was highly effective among people with acute and recent HCV infection, supporting further evaluation of shortened-duration pan-genotypic therapy in this setting.

Keyphrases

hepatitis c virus
liver failure
cell therapy
bone marrow
aortic dissection